Literature DB >> 24227851

Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.

Justine Sunshine1, Moon Kim, Jonathan M Carlson, David Heckerman, Julie Czartoski, Stephen A Migueles, Janine Maenza, M Juliana McElrath, James I Mullins, Nicole Frahm.   

Abstract

A major challenge in the development of an HIV vaccine is that of contending with the extensive sequence variability found in circulating viruses. Induction of HIV-specific T-cell responses targeting conserved regions and induction of HIV-specific T-cell responses recognizing a high number of epitope variants have both been proposed as strategies to overcome this challenge. We addressed the ability of cytotoxic T lymphocytes from 30 untreated HIV-infected subjects with and without control of virus replication to recognize all clade B Gag sequence variants encoded by at least 5% of the sequences in the Los Alamos National Laboratory HIV database (1,300 peptides) using gamma interferon and interleukin-2 (IFN-γ/IL-2) FluoroSpot analysis. While targeting of conserved regions was similar in the two groups (P = 0.47), we found that subjects with control of virus replication demonstrated marginally lower recognition of Gag epitope variants than subjects with normal progression (P = 0.05). In viremic controllers and progressors, we found variant recognition to be associated with viral load (r = 0.62, P = 0.001). Interestingly, we show that increased overall sequence coverage, defined as the overall proportion of HIV database sequences targeted through the Gag-specific repertoire, is inversely associated with viral load (r = -0.38, P = 0.03). Furthermore, we found that sequence coverage, but not variant recognition, correlated with increased recognition of a panel of clade B HIV founder viruses (r = 0.50, P = 0.004). We propose sequence coverage by HIV Gag-specific immune responses as a possible correlate of protection that may contribute to control of virus replication. Additionally, sequence coverage serves as a valuable measure by which to evaluate the protective potential of future vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227851      PMCID: PMC3911649          DOI: 10.1128/JVI.02361-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Authors:  Yi Liu; John McNevin; Jianhong Cao; Hong Zhao; Indira Genowati; Kim Wong; Sherry McLaughlin; Matthew D McSweyn; Kurt Diem; Claire E Stevens; Janine Maenza; Hongxia He; David C Nickle; Daniel Shriner; Sarah E Holte; Ann C Collier; Lawrence Corey; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  A very high level of crossreactivity is an essential feature of the T-cell receptor.

Authors:  D Mason
Journal:  Immunol Today       Date:  1998-09

3.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.

Authors:  Todd M Allen; Xu G Yu; Elizabeth T Kalife; Laura L Reyor; Mathias Lichterfeld; Mina John; Michael Cheng; Rachel L Allgaier; Stanley Mui; Nicole Frahm; Galit Alter; Nancy V Brown; Mary N Johnston; Eric S Rosenberg; Simon A Mallal; Christian Brander; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control.

Authors:  Rosario Zuñiga; Aldo Lucchetti; Patricia Galvan; Shyla Sanchez; Carmen Sanchez; Ana Hernandez; Hugo Sanchez; Nicole Frahm; Caitlyn H Linde; Hannah S Hewitt; William Hildebrand; Marcus Altfeld; Todd M Allen; Bruce D Walker; Bette T Korber; Thomas Leitner; Jorge Sanchez; Christian Brander
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

7.  HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.

Authors:  Emma L Turnbull; A Ross Lopes; Nicola A Jones; David Cornforth; Phillipa Newton; Diana Aldam; Pierre Pellegrino; Jo Turner; Ian Williams; Craig M Wilson; Paul A Goepfert; Mala K Maini; Persephone Borrow
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

8.  Biological and virologic characteristics of primary HIV infection.

Authors:  T W Schacker; J P Hughes; T Shea; R W Coombs; L Corey
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

9.  Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.

Authors:  Todd M Allen; Marcus Altfeld; Shaun C Geer; Elizabeth T Kalife; Corey Moore; Kristin M O'sullivan; Ivna Desouza; Margaret E Feeney; Robert L Eldridge; Erica L Maier; Daniel E Kaufmann; Matthew P Lahaie; Laura Reyor; Giancarlo Tanzi; Mary N Johnston; Christian Brander; Rika Draenert; Jurgen K Rockstroh; Heiko Jessen; Eric S Rosenberg; Simon A Mallal; Bruce D Walker
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

10.  Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection.

Authors:  Helen Horton; Ian Frank; Ruth Baydo; Emilie Jalbert; Justin Penn; Sean Wilson; John P McNevin; Matthew D McSweyn; Deborah Lee; Yunda Huang; Stephen C De Rosa; M Juliana McElrath
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

View more
  15 in total

1.  HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.

Authors:  Florencia Pereyra; David Heckerman; Jonathan M Carlson; Carl Kadie; Damien Z Soghoian; Daniel Karel; Ariel Goldenthal; Oliver B Davis; Charles E DeZiel; Tienho Lin; Jian Peng; Alicja Piechocka; Mary Carrington; Bruce D Walker
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

2.  Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.

Authors:  Sushma Boppana; Andrew Fiore-Gartland; Anju Bansal; Paul Goepfert
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

3.  Conserved HIV-1 Gag p24 Epitopes Elicit Cellular Immune Responses That Impact Disease Outcome.

Authors:  Leandro F Tarosso; Vinicius A Vieira; Mariana M Sauer; Helena I Tomiyama; Jorge Kalil; Esper G Kallas
Journal:  AIDS Res Hum Retroviruses       Date:  2017-08-03       Impact factor: 2.205

4.  In chronic infection, HIV gag-specific CD4+ T cell receptor diversity is higher than CD8+ T cell receptor diversity and is associated with less HIV quasispecies diversity.

Authors:  Mark A Pilkinton; Wyatt J McDonnell; Louise Barnett; Abha Chopra; Rama Gangula; Katie D White; Shay Leary; Jennifer Currenti; Silvana Gaudieri; Simon A Mallal; Spyros A Kalams
Journal:  J Virol       Date:  2021-02-03       Impact factor: 5.103

5.  Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.

Authors:  Justine E Sunshine; Brendan B Larsen; Brandon Maust; Ellie Casey; Wenje Deng; Lennie Chen; Dylan H Westfall; Moon Kim; Hong Zhao; Suvankar Ghorai; Erinn Lanxon-Cookson; Morgane Rolland; Ann C Collier; Janine Maenza; James I Mullins; Nicole Frahm
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

6.  The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.

Authors:  Anne Bet; Emmanuel Atangana Maze; Anju Bansal; Sarah Sterrett; Antoine Gross; Stéphanie Graff-Dubois; Assia Samri; Amélie Guihot; Christine Katlama; Ioannis Theodorou; Jean-Michel Mesnard; Arnaud Moris; Paul A Goepfert; Sylvain Cardinaud
Journal:  Retrovirology       Date:  2015-02-10       Impact factor: 4.602

7.  CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Authors:  Stephen A Migueles; Daniel Mendoza; Matthew G Zimmerman; Kelly M Martins; Sushila A Toulmin; Elizabeth P Kelly; Bennett A Peterson; Sarah A Johnson; Eric Galson; Kate O Poropatich; Andy Patamawenu; Hiromi Imamichi; Alexander Ober; Catherine A Rehm; Sara Jones; Claire W Hallahan; Dean A Follmann; Mark Connors
Journal:  EBioMedicine       Date:  2014-12-22       Impact factor: 8.143

8.  Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays.

Authors:  Sylvia Janetzki; Markus Rueger; Tomas Dillenbeck
Journal:  Cells       Date:  2014-11-27       Impact factor: 6.600

9.  Triple Cytokine FluoroSpot Analysis of Human Antigen-Specific IFN-γ, IL-17A and IL-22 Responses.

Authors:  Tomas Dillenbeck; Eva Gelius; Jenny Fohlstedt; Niklas Ahlborg
Journal:  Cells       Date:  2014-11-27       Impact factor: 6.600

10.  Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.

Authors:  Anne-Marie Carola Andersson; Peter Johannes Holst
Journal:  J Transl Med       Date:  2016-12-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.